The aims of EUPATI CH are to act as the central point for inquiries and cooperation platform for patient empowerment and involvement in medicines R&D processes in Switzerland.
1. Contributing to patient empowerment for active involvement in medicines research and development (R&D).
2. Supporting public awareness raising for the EUPATI education material.
3. Fostering partnerships with medicines R&D stakeholders in Switzerland to promote public involvement in all aspects of medicines R&D.
EUPATI CH is a nonprofit organisation. In order to fullfill our aims and retain our independence, we need financial support.
EUPATI CH acknowledges any funds and grants. Please do not hesitate to contact us.
Bank account details
Swiss postfinance account:
IBAN: CH84 0900 0000 8956 5298 4
Bodies of EUPATI CH
- The General Assembly of EUPATI CH,
- The Executive Board,
- The Auditors,
- The Advisory Board.
European Patient’s Academy on Therapeutic Innovation (EUPATI CH)
Switzerland / Schweiz / Suisse / Svizzera
℅ SCTO, Effingerstrasse 35, 3008 Bern, Switzerland
+41 31 307 10 40
Please send your completed application form for membership to the Executive Board, via its secretariat. By applying for membership (in writing or verbally) you automatically agree with our statutes.
The Executive Board will inform you on its decision on your membership application.
Categories of membership
EUPATI CH has the following membership categories:
- Ordinary members: individual persons,
- Ordinary members: institution representatives
- Supporting members with no voting rights: institutions who wish to financially support without conditions
You can download the application form here
Membership fees for 2018 were determined by the General Assembly on October 26, 2017, a hardship clause exists for individuals who cannot pay this amount (statutes):
- Individual persons: CHF 30.-
- Institutions / Organisations: at least CHF 50.- (but are most welcome to pay a higher amount)
- Supporting Institutions / Organisations: CHF 2000.-
Newsletter EUPATI CH
Strategy and Workplan
Strategy and workplan of the EUPATI CH association 2017 - 2020 is available on request at the secretariat.
Support for the implementation of the workplan 2018/2019 is being received by:
- Janssen-Cilag AG
- Pfizer AG
- Roche Pharma (Schweiz) AG
- Takeda Pharma AG
Publications and Articles
EUPATI CH Flyers and Postcards
Patient representatives and organisations
Swiss Forum Lung Cancer
FMF & AID Global Association
Schweizerische Morbus Crohn / Colitis ulcerosa Vereinigung (SMCC )
Patient Advocate for Cancer Research and Treatment (PACRT)
Verband Nierenpatienten Schweiz (VNPS)
Association Romande du Syndrome de Sjögren
Academic representatives and organisations
University Hospital Basel (USB)
Ente Ospedaliero Cantonale (EOC)
Swiss Clinical Trial Organisation (SCTO)
Schweizerische Arbeitsgemeinschaft für Klinsche Krebsforschung ( SAKK)
Clinical Trials Center, University Hospital Zürich
Dr. Brigitte Franke-Bray
Prof. Uyen Huynh-Do
Dr. Julia Amann
Debra De Silva-Sun
Anne-Lise Ducournau Lichtenberg
Larisa Aragon Castro
Ivo Schauwecker (Patient and academic representative)
Hansruedi Völkle (Positivrat Schweiz)
Caecilia Schmid (SCTO)
open for application
open for application
Other board members
Rosmarie Pfau (lymphome.ch, EUPATI Fellow)
Marie Mi Bonde Hansen (USB Basel)
Cristiana Sessa (EOC Ticino)
Annette Magnin (SCTO)
Larisa Aragon (Patient and academic representative)
Stephan Schobinger (Patient and academic representative)
Catherine Bates (Academic representative)
Our Advisory Board (AB) shall provide non-binding expert advice and guidance and support EUPATI CH strategically, read more about your roles here.
Membership of the Advisory Board (AB) is open to all patients, patient advocates, patient organisations, consumer organisations, academics, institutions, university hospitals, healthcare associations, industry representatives, companies, government agencies representatives, regulatory authorities, medical journalists and anyone interested.
A request to become an Advisory Board member of EUPATI CH shall be sent to the Executive Board by sending an email to the secretariat indicating the intent and commitment to support the platform.